Seletalisib (UCB5857) | UCB
UCB's Global Corporate Website

Seletalisib (UCB5857)

Disease area studied Abbreviated title Phase Study ID Registry database Study results Plain language summary Publication (if available)
APDS An Open-Label, Exploratory, Multicenter, Extension Study to Evaluate the Long-Term Safety, Tolerability, Pharmacokinetics and Efficacy of UCB5857 in Subjects with Activated Phosphoinositide 3 Kinase (PI3K) Delta Syndrome (APDS) Phase 3 APD003
2015-005541-30 LINK
Sjogren´s Syndrome A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy of UCB5857 Over 12 Weeks in Subjects With Primary Sjorgen's Syndrome Phase 2 SS0004
Juarez M., Diaz N., Johnston G.I., Nayar S., Payne A. et al. Rheumatology 2021, 60(3):1364-1375